Adjuvants in vaccines and for immunisation: Current trends

Expert Opinion on Biological Therapy

Volumn 7, Issue 10, 2007, Pages 1551-1562

  Chiarella, Pieranna ^b,c   Massi, Emanuela ^b   De Robertis, Mariangela ^b   Signori, Emanuela ^a   Fazio, Vito Michele ^b,d  

^a CNR   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^c Bio Ker Srl ^*  (Italy)

^d CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

Adjuvant; Immune response; Vaccine

Indexed keywords

ADJUVANT; ALPHA INTERFERON; ALUMINUM SALT; CHEMOKINE; CYTOKINE; DEFENSIN; FLT3 LIGAND; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; LIPOPOLYSACCHARIDE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; TOLL LIKE RECEPTOR; IMMUNOLOGICAL ADJUVANT;

ALLERGY; ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; ELECTROPORATION; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNIZATION; INFECTION; INFLAMMATORY DISEASE; INNATE IMMUNITY; PROTEOLIPOSOME; REVIEW; VACCINATION; ANIMAL; CELLULAR IMMUNITY; CHEMISTRY; DRUG DESIGN; DRUG EFFECT; HUMAN;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; DRUG DESIGN; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, NATURAL; VACCINATION;

EID: 35348843400     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.7.10.1551     Document Type: Review

References (92)

1. JANEWAY CA: Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb. Symp. Quant. Biol. (1989) 54(Part 1):1-13.
2. BARTON GM, MEDZHITOV R: Toll-like receptors and their ligands. Curr. Top. Microbiol. Immunol. (2002) 270:81-92. • This paper focuses on the role of TLRs in the innate immune response and on their numerous ligands.
3. FREUND J, CASALS J, PAGE-HOSMER E: Sensitization and antibody formation after injection of tubercle bacilli and paraffin oil. Proc. Soc. Exp. Biol. Med. (1937) 37:509-513.
4. ULMER AJ, RIETSCHEL E, ZAHRINGHER U, HEINE H: Lipopolysaccharide: structure, bioactivity, receptors and signal transduction. Trends Glycosci. Glycotechnol. (2002) 14(76):53-68.
5. ISMAILI J, RENNESSON J, ASKOV E et al.: Monophosphoryl lipid A activates both human dendritic cells and T-cells. J. Immunol. (2002) 168:926-932.
6. JOHNSON DA, KEEGAN DS, SOWELL CG et al.: 3-O-desacyl monophosphoryl lipid A derivatives: synthesis and immunostimulant activities. J. Med. Chem. (1999) 42(22):4640-4649.
7. KRIEG AM: From A to Z on CpG. Trends Immunol. (2002) 23(2):64-65.
8. WAGNER H: Bacterial CpG DNA activates immune cells to signal infectious danger. Adv. Immunol. (1999) 73:329-368.
9. HARTMANN G, WEERATNA RD, BALLAS ZK et al.: Delineation of a CpG phosphorothioate oligodeoxynudeotide for activating primate immune responses in vitro and in vivo. J. Immunol. (2000) 164(3):1617-1624.
10. CIAFRE' SA, RINALDI M, GASPARINI P et al.: Stability and functional effectiveness of phosphorothioate modified duplex DNA and synthetic 'mini-genes'. Nucleic Acids Res. (1995) 23:4134-4142.
11. KLINMAN DM, BARNHART KM, CONOVER J: CpG motifs as immune adjuvants. Vaccine (1999) 17(1):19-25.
12. FELTQUATE DM, HEANEY S, WEBSTER RG, ROBINSON HL: Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J. Immunol. (1997) 158:2278-2284.
13. BARRY MA, JOHNSTON SA: Biological features of genetic immunization. Vaccine (1997) 15:788-791.
14. PEREZ O, BRACHO G, LASTRE M et al.: Proteoliposome-derived Cochleate as an immunomodulator for nasal vaccine. Vaccine (2006) 24(Suppl. 2):S2/52-S2/53.
15. RODRIGUEZ T, PEREZ O, UGRINOVIC S, BRACHO G, MASTROENI P: Bacterial derived proteoliposomes as ideal delivery system and cellular adjuvants. Vaccine (2006) 24(Suppl. 2):S2/24-S2/25.
16. DEL CAMPO J, LASTRE M, BRACHO G et al.: Immunological evaluation of bacterial Cochleate and proteoliposome as mucosal adjuvants. Vaccine (2006) 24(Suppl. 2):S2/50-S2/51.
17. HERBERT WJ: Antigenicity of soluble protein in the presence of high levels of antibody: a possible mode of action of the antigen adjuvants. Nature (1966) 210(5037):747-748.
18. HERBERT WJ: The mode of action of mineral oil emulsion adjuvants on antibody production in mice. Immunology (1968) 14:301-318.
19. PASHINE A, VALIANTE NM, ULMER JB: Targeting the innate immune response with improved vaccine adjuvants. Nat. Med. (2005) 11:S63-S68.
20. BRAMWELL VW, PERRY Y: Particulate delivery systems for vaccine. Crit. Rev. Ther. Drug Carrier Syst. (2005) 22:151-214.
21. KENNEY RT, EDELMAN R: Survey of human-use adjuvants. Expert Rev. Vaccines (2003) 2(2):167-188.
22. ULMER JB, DEWITT CM, CHASTAIN M et al.: Enhancement of DNA vaccine potency using conventional aluminum adjuvants. Vaccine (1999) 18(1-2):18-28.
23. GALLUCCI S, LOLKERNA M, MATZINGER P: Natural adjuvants: endogenous activators of dendritic cells. Nat. Med. (1999) 5:1249-1252. • This article suggests endogenous signals derived from stressed, necrotic or virally infected cells may be natural adjuvants for dendritic cells activation.
24. MCMAHON JM, SIGNORI E, WELLS KE, FAZIO VM, WELLS DJ: Optimisation of electrotransfer of plasmid into skeletal muscle by pretreatment with hyaluronidase increased expression with reduced muscle damage. Gene Ther. (2001) 8(16):1264-1270.
25. GALLUCCI S, MATZINGER P: Danger signals: SOS to the immune system. Curr. Opin. Immunol. (2001) 13(1):114-119. • This review demonstrates how the immune system can be activated by danger signals liberated after tissue damage and stress.
26. BABIUK S, BACA-ESTRADA ME, FOLDVARI M et al.: Increased gene expression and inflammatory cell infiltration caused by electroporation are both important for improving the efficacy of DNA vaccines. J. Biotechnol. (2004) 110(1):1-10.
27. + T-cell responses. Gene Ther. (2003) 10:717-724.
28. MCMAHON JM, WELLS KE, BAMFO JE, CARTWRIGHT MA, WELLS DJ: Inflammatory responses following direct injection of plasmid DNA into skeletal muscle. Gene Ther. (1998) 5:1283-1290.
29. JACOBSEN NE, FAIRBROTHER WJ, KENSIL CR et al.: Structure of the saponin adjuvant QS-21 and its base-catalyzed isomerization product by 1H and natural abundance 13C NMR spectroscopy. Carbohydr. Res. (1996) 280:1-14.
30. MOORE A, McCARTHY L, MILLS KH: The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1. Vaccine (1999) 17:2517-2527.
31. MARCIANI DJ, REYNOLDS RC, PATHAK AK et al.: Fractionation, structural studies and immunological characterization of the semisynthetic quillaja saponis derivative GP-0100. Vaccine (2003) 21:3961-3971.
32. MERALDI V, AUDRAN R, ROMERO JF et al.: OM-174, a new adjuvant with a potential for human use, induces a protective response when administered with the synthetic C-terminal fragment 242 - 310 from the circumsporozoite protein of Plasmodium berghei. Vaccine (2003) 21:2485-2491.
33. AUDRAN R, CORRADIN G, DRUILHE P et al.: Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. Infect. Immun. (2005) 73:8017-8026.
34. BALLARD JD, COLLIER RJ, STARNBACH MN: Antrax toxin-mediated delivery of a cytotoxic T-cell epitope in vivo. Proc. Natl. Acad. Sci. USA (1996) 93(22):12531-12534.
35. CARBONETTI NH, IRISH TJ, CHEN CH et al.: Intracellular delivery of a cytolytic T-lymphocyte epitope peptide by pertussis toxin to major histocompatibility complex class I without involvement of the cytosolic class I antigen processing pathway. Infect. Immun. (1999) 67:602-607.
36. STEVENSON FK, RICE J, OTTENSMEIER CH, THIRDBOROUGH SM, ZHU D: DNA fusion vaccine against cancer: from the laboratory to the clinic. Immunol. Rev. (2004) 199:156-180.
37. KHAN CMA, VILLAREAL-RAMOS B, PIERCE RJ et al.: Construction, expression and immunogenicity of the Schistosoma mansoni P28 glutathione S-transferase as agenetic fusion to tetanus toxin fragment C in a live Aro attenuated vaccine strain of Salmonella. Proc. Natl. Acad. Sci. USA (1994) 91:11261-11265.
38. KHAN CMA, VILLAREAL-RAMOS B, PIERCE RJ et al.: Construction, expression and immunogenicity of multiple tandem copies of the Schistosoma mansoni peptide comprising amino acids 115 - 131 of the P28 glutathione S-transferase, expressed as C-terminal fusions to tetanus toxin fragment C in a live Aro attenuated vaccine strain of Salmonella. J. Immunol. (1994) 153:5634-5642.
39. RICE J, BUCHAN S, STEVENSON FK: Critical components of a DNA fusion vaccine able to induce protective cytotoxic T cells against a single epitope of a tumour antigen. J. Immunol. (2002) 169:3908-3913.
40. KING CA, SPELLBERG MB, ZHU D et al.: DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat. Med. (1998) (11):1281-1286.
41. UMLAND TC, WINGERT LM, SWAMINATHAN S, FUREY WF, SCHMIDT JJ, SAX M: Structure of the receptor binding fragment HC of tetanus neurotoxin. Nat. Struct. Biol. (1997) 4:788-792.
42. PANINA-BORDIGNON, TAN A, TERMIJTELEN A, DEMOTZ S, CORRADIN G, LANZAVECCHIA A: Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur. J. Immunol. (1989) 19(12):2237-2242. •• One of the first papers to show the presence of universally immunogenic T cell epitopes in tetanus toxin fragment C.
43. SPELLERBERG MB, ZHU D, THOMPSETT A, KING CA, HAMBLIN TJ, STEVENSON FK: DNA vaccines against lymphoma: promotion of anti-idiotypic antibody responses induced by single chain Fv genes by fusion to tetanus toxin fragment C. J. Immunol. (1997) 159(4):1885-1892.
44. RICE J, ELLIOTT T, BUCHAN S, STEVENSON FK: DNA fusion vaccine designed to induce cytotoxic T cell responses against defined peptide motifs: implications for cancer vaccines. J. Immunol. (2001) 167:1558-1565.
45. FALUGI F, PETRACCA R, MARIANI M et al.: Rationally designed strings of promiscuous CD4(+) T cell epitopes provide help to Haemophilus influenzae type B oligosaccharide: a model for new conjugate vaccines. Eur. J. Immunol. (2001) 31:3816-3824.
46. DEMOTZ S, BARBEY C, CORRADIN G, AMOROSO A, LANZAVECCHIA A: The set of naturally processed peptides displayed by DR molecules is tuned by polymorphism of residue 86. Eur. J. Immunol. (1993) 23:425-432.
47. HO PC, MUTCH DA, WINKEL KD et al.: Identification of two promiscuous T cell epitopes from tetanus toxin. Eur. J. Immunol. (1990) 20:477-483.
48. BARALDO K, MORI E, BARTOLONI A et al.: N19 polyepitope as a carrier for enhanced immunogenicity and protective efficacy of meningococcal conjugate vaccines. Infect. Immun. (2004) 72(8):4884-4887. •• One of the first demonstrations of the successful peptide vaccination with a string of universal T-cell epitopes.
49. BARALDO K, MORI E, BARTOLONI A et al.: Combined conjugate vaccines: enhanced immunogenicity with the N19 polyepitope as a carrier protein. Infect. Immun. (2005) 73(9):5835-5841.
50. + IFN-γ and Th lymphocyte responses: evaluation of multiepitope polypeptides as a mode for vaccine delivery. J. Immunol. (2002) 168:6189-6198.
51. ISHIOKA GY, FIKES J, HERMANSON G et al.: Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes. J. Immunol. (1999) 162:3915-3925. •• One of the first papers to show the rationale and the effects of minigene DNA vaccines encoding several HLA-restricted CTL epitopes.
52. WIDMANN C, ROMERO P, MARYANSKI JL, CORRADIN G, VALMORI D: T-helper epitopes enhance the cytotoxic response of mice immunized with MHC class I-restricted malaria peptides. J. Immunol. Methods (1992) 155:95-99.
53. TYMCIU S, DURIEUX-ALEXANDRENNE C, WIJKHUISEN A et al.: Enhancement of antibody responses in DNA vaccination using a vector encoding a universal T-helper cell epitope. DNA cell Biol. (2004) 23(6):395-402.
54. ASTORI M, KRAEHENBUHL JP: Recombinant fusion peptides containing single or multiple repeats of a ubiquitous T-helper epitope are highly immunogenic. Mol. Immunol. (1996) 33(13):1017-1024.
55. ALEXANDER J, SIDNEY J, SOUTHWOOD S et al.: Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity (1994) 1(9)751-761.
56. ALEXANDER J, DEL GUERCIO MF, MAEWAL A et al.: Linear PADRE T helper epitope and carbohydrate B cell epitope conjugates induce specific high titer IgG antibody responses. J. Immunol. (2000) 164:1625-1633.
57. FRANKE ED, HOFFMAN SL, SACCI JB et al.: Pan DR binding sequence provides T-cell help for induction of protective antibodies against Plasmodium yoelii sporozoites. Vaccine (1999) 17:1201-1205.
58. DEL GUERCIO MF, ALEXANDER J, KUBO RT et al.: Potent immunogenic short linear peptide constructs composed of B cell epitopes and Pan DR T helper epitopes (PADRE) for antibody responses in vivo. Vaccine (1997) 15(4):441-448.
59. SETTE A, BUUS S, COLON S, SMITH JA, MILES C, GREY HM: Structural characteristics of an antigen required for its interaction with Ia and recognition by T cells. Nature (1987) 328:395-399. •• One of the first papers on the characterization of a universal T helper epitope (PADRE) derived from ovalbumin sequence.
60. CIAFRE' SA, RINALDI M, VESPIGNANI I et al.: A plasmid family containing two different expression cassettes suitable for immunomodulation and genetic immunization. Plasmid (1998) 40:84-89.
61. GOOD MF, POMBO D, LUNDE MN et al.: Recombinant human interleukin-2 (IL-2) overcomes genetic nonresponsiveness to malaria sporozoite peptides. Correlation and effect with biological activity. J. Immunol. (1988) 141:972-977.
62. RINALDI M, RIA F, PARRELLA P et al.: Antibodies elicited by naked DNA vaccination against the complementary-determining region 3 hypervariable region of immunoglobulin heavy chain idiotypic determinants of B-lymphoproliferative disorders specifically react with patients' tumor cells. Cancer Res. (2001) 61-64:1555-1562.
63. ROSENBERG SA, YANG JC, SCHWARTZENTRUBER DJ et al.: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. (1998) 4:321-327.
64. BAROUCH DH, SANTRA S, STEENBEKE TD et al.: Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration. J. Immunol. (1998) 161(4):1875-1882.
65. SETOGUCHI R, HORI S, TAKAHASHI T, SAKAGUCHI S: Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J. Exp. Med. (2005) 201:723-735.
66. BAYER AL, YU A, ADEEGBE D, MALEK TR: Essential role for interleukin-2 for CD4(+)CD25(+) T regulatory cell development during the neonatal period. J. Exp. Med. (2005) 201(5):769-777.
67. ATKINS MB, ROBERTSON MJ, GORDON M et al.: Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin. Cancer Res. (1997) 3(3):409-417.
68. GOLLOB JA, MIER JW, VEENSTRA K: Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-γ induction is associated with clinical response. Clin. Cancer Res. (2000) 6(5):1678-1694.
69. HADDAD D, RAMPRAKASH J, SEDEGAH M: Plasmid vaccine expressing granulocyte-macrophage colony-stimulating factor attracts infiltrates including immature dendritic cells into injected muscles. J. Immunol. (2000) 165(7):3772-3781.
70. + T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF. J. Immunol. (2002) 168(2):562-568.
71. DRANOFF G, JAFFEE E, LAZENBY A et al.: Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA (1993) 90(8):3539-3543.
72. DISIS ML, BERNHARD H, SHIOTA FM et al.: Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood (1996) 88:202-210.
73. FU XY, WATSON G, JIMENEZ JJ et al.: Expansion of immunoregulatory macrophages by granulocyte-macrophage colony-stimulating factor derived from a mammary tumor. Cancer Res. (1990) 50:227-234.
74. OWEN JL, LOPEZ DM, GROSSO JF et al.: The expression of CCL2 by T lymphocytes of mammary tumor bearers: role of tumor derived factors. Cell Immunol. (2005) 235:122-135.
75. SUMIDA SM, MCKAY PF, TRUITT DM et al.: Recruitment and expansion of dendritic cells in vivo potentiate the immunogenicity of plasmid DNA vaccines. J. Clin. Invest. (2004) 114(9):1334-1342.
76. LYNCH DH, ANDREASEN A, MARASKOVSKY E, WHITMORE J, MILLER RE, SCHUH JC: Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat. Med. (1997) 3:625-631.
77. CHEN K, BRAUN S, LYMAN S et al.: Antitumour activity and immunotherapeutic properties of Flt-3 ligand in a murine breast cancer model. Cancer Res. (1997) 57(16):3511-3516.
78. SHIMAO K, TAKAYAMA T, ENOMOTO K et al.: Cancer gene therapy using in vivo electroporation of Flt3-ligand. Int. J. Oncol. (2005) 2:457-463.
79. PERON JM, ESCHE C, SUBBOTIN VM, MALISZEWSKI C, LOTZE MT, SHURIN MR: FLT3-ligand administration inhibits liver metastases: role of NK cells. J. Immunol. (1998) 161:6164-6170.
80. LEHRER RI, BARTO A, DAHER KA, HARWIG SS, GANZ T, SELSTED ME: Interaction of human defensins with Escherichia coli. Mechanism of bactericidal activity. J. Clin. Invest. (1989) 84(2):553-561.
81. YANG D, CHERTOV O, BYKOVSKAIA SN et al.: β-Defensins: linking innate and adaptive immunity through dendritic and T cell CCR6. Science (1999) 286:525-528.
82. NIYONSABA F, OGAWA H, NAGAOKA I: Human β-defensin-2 functions as chemotactic agent for TNF-α treated human neutrophils. Immunology (2004) 111:273-281.
83. BIRAGYN A, SURENHU M, YANG D et al.: Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens. J. Immunol. (2001) 167:6644-6653.
84. LILLARD JW Jr, BOYAKA PN, CHERTOV O, OPPENHEIM JJ, MCGHEE JR: Mechanisms for induction of acquired host immunity by neutrophil peptide defensins. Proc. Natl. Acad. Sci. USA (1999) 96:651-656.
85. DONALD CD, SUN CQ, LIM SD et al.: Cancer-specific loss of β-defenisn 1 in renal and prostatic carcinomas. Lab. Invest. (2003) 83:501-505.
86. NIYONSABA F, USHIO H, NAGAOKA I, OKUMURA K, OGAWA H: The human β-defensins (-1,-2,-3,-4) and cathelicidin LL-37 induce IL-18 secretion through p38 and ERK MAPK activation in primary human keratinocytes. J. Immunol. (2005) 175:1776-1784.
87. YANG D, BIRAGYN A, HOOVER DM, LUBKOWSKI J, OPPENHEIM JJ: Multiple roles of antimicrobial defensins, cathelicidins, and eosinophil-derived neurotoxin in host defense. Annu. Rev. Immunol. (2004) 22:181-215.
88. BROGDEN KA, HEIDARI M, SACCO RE et al.: Defensin-induced adaptive immunity in mice and its potential in preventing periodontal disease. Oral Microbiol. Immunol. (2003) 18:95-99.
89. TANI K, MURPHY WJ, CHERTOV O et al.: Defensins act as potent adjuvants that promote cellular and humoral immune responses in mice to a lymphoma idiotype and carrier antigens. Int. Immunol. (2000) 12:691-700.
90. JEGO G, PALUCKA AK, BLANCK JP, CHALOUNI C, PASCUAL V, BANCHEREAU J: Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity (2003) 19:225-234.
91. TOVEY MG, LALLEMAND C, MERITET JF, MAURY C: Adjuvant activity of interferon α: mechanism(s) of action. Vaccine (2006) 24(Suppl. 2):S2/46-S2/47.
92. OKADA H, TSUGAWA T, SATO H et al.: Delivery of interferon-α transfected dendritic cells into central nervous system tumours enhances the antitumor efficacy of peripheral peptide-based vaccines. Cancer Res. (2004) 64:5830-5838.